R J Spiegel1. Show Affiliations » 1. Clinical Research Division, Schering Corporation, Kenilworth, NJ 07033.
Abstract
Entities: Disease
Mesh: See more » Carcinoid Tumor/therapyCarcinoma, Basal Cell/therapyHepatitis, Chronic/therapyHumansInterferon Type I/adverse effectsInterferon Type I/therapeutic useIntestinal Neoplasms/therapyRecombinant ProteinsSkin Neoplasms/therapy
Substances: See more » Interferon Type IRecombinant Proteins
Year: 1988 PMID: 3057643
Source DB: PubMed Journal: Semin Oncol ISSN: 0093-7754 Impact factor: 4.929